Verastem raises fresh capital, shares trade in biotech spotlight on Nasdaq
Published on 06/22/2026 at 16:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 16:41.
Verastem Inc (US92335V1008) completed a public offering of common shares and pre-funded warrants in early June, adding fresh capital to its balance sheet while its high-beta biotech stock continues to trade on Nasdaq. The transaction parameters and subsequent analyst commentary frame the current risk-reward picture for the shares.
What the capital raise delivered
According to the company’s June 2026 offering documents filed with the SEC, Verastem sold new common shares together with pre-funded warrants, raising gross proceeds in the tens of millions of US dollars to support clinical development and general corporate purposes.SEC prospectus supplement for the June 2026 Verastem offering The additional equity capital increases financial flexibility for ongoing oncology trials but also adds dilution for existing shareholders.
The new securities were issued at a discount to the prior Nasdaq closing price, a common pattern for small-cap biotech placements, and included warrants that could bring in further funds if exercised at the pre-agreed strike price.Verastem investor news and filings overview The raise follows earlier financings that together underline the company’s dependence on capital markets to fund late-stage clinical programs.
Analyst expectations for the Verastem stock
Consensus data compiled by Bitget from Wall Street research shows a 12-month Verastem target price of 8.52 US dollars, with individual estimates ranging from 4.14 to 12.21 US dollars, versus a recent closing price of 4.12 US dollars.Analyst target summary for Verastem shares This implies notable upside potential if the company executes on its pipeline milestones.
The same data set cites even higher scenario ranges for later years, with some long-term projections for 2030 between 8.24 and 41.20 US dollars, underscoring how strongly analyst models hinge on clinical trial success in oncology indications.Long-term Verastem valuation scenarios With Verastem shares listed on Nasdaq under the ticker VSTM, the stock trades in a sector environment shaped by peers such as Exelixis, Blueprint Medicines and Mirati-focused assets at larger players.
All news and analysis on the Verastem shares
Key figures, ad-hoc releases and further analyst assessments on Verastem can be found in the dedicated topic section and on the company’s investor relations page.
The oncology pipeline behind the ticker
Verastem focuses on targeted cancer therapies, notably RAF/MEK and RAS pathway inhibitors, with lead assets advancing in solid tumor indications where current treatment options remain limited.Verastem pipeline description The company’s strategy concentrates on combinations and biomarker-selected populations to improve response rates and durability.
Where the shares trade today
Verastem shares (US92335V1008) most recently closed on Nasdaq at 4.12 US dollars, based on Bitget data for the last trading day cited in June 2026.VSTM quote and overview
Key data on the Verastem shares
- Company: Verastem, Inc.
- ISIN: US92335V1008
- WKN: A1JQ4Z
- Ticker: VSTM
- Trading venue: Nasdaq
- Price (as of 2026-06-18, 16:00): 4.12 USD
- Market cap: 0.28 billion USD (as of 2026-06-18)
- Sector / industry: Biotechnology / Oncology
- Index membership: not part of a major headline index such as S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a recommendation to buy or sell any financial instrument. Figures and assessments are based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
